Group 1 - Living Homeopathy International submitted an IPO application to the SEC, aiming to raise up to $6 million with a proposed stock price range of $4 to $6 for 1.3 million shares, resulting in a market valuation of approximately $56 million [1][6] - The company offers health products, including homeopathic medicines (9% of FY2024 revenue), homeopathic adjunctive medicines (80%), and flower remedies (4%), with a leading market share of 41% in Hong Kong's homeopathic product market as of 2023 [2] - Founded in 1994 and headquartered in Hong Kong, the company reported sales of $8 million for the 12 months ending September 30, 2024 [5] Group 2 - The exclusive bookrunner for the IPO is US Tiger Securities, with pricing terms yet to be disclosed [6]